LLYELI LILLY & Co

NYSE lilly.com


$ 913.93 $ 8.55 (0.94 %)    

Monday, 01-Jul-2024 13:42:45 EDT
QQQ $ 480.98 $ 0.69 (0.14 %)
DIA $ 391.68 $ 0.55 (0.14 %)
SPY $ 545.14 $ -0.27 (-0.05 %)
TLT $ 89.98 $ -0.43 (-0.48 %)
GLD $ 215.43 $ 0.42 (0.2 %)
$ 905.38
$ 911.53
$ 913.79 x 100
$ 915.00 x 106
$ 904.65 - $ 916.52
$ 431.12 - $ 915.54
3,375,426
na
818.28B
$ 0.57
$ 133.31
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-30-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-01-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 04-30-2021 03-31-2021 10-Q
14 02-17-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-31-2020 06-30-2020 10-Q
17 05-01-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-25-2019 09-30-2019 10-Q
20 08-02-2019 06-30-2019 10-Q
21 05-02-2019 03-31-2019 10-Q
22 02-19-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 07-25-2018 06-30-2018 10-Q
25 04-27-2018 03-31-2018 10-Q
26 02-20-2018 12-31-2017 10-K
27 10-27-2017 09-30-2017 10-Q
28 07-28-2017 06-30-2017 10-Q
29 05-01-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-29-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 07-30-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 02-19-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-28-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sanofi-nears-decision-on-16b-upgrade-for-frankfurt-insulin-plant

Sanofi is set to invest up to $1.6 billion in its Frankfurt insulin production site, marking a significant win for Germany'...

 cantor-fitzgerald-reiterates-overweight-on-eli-lilly-and-co-maintains-885-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.

 eli-lilly-soars-to-52-week-high-can-the-momentum-continue

Eli Lilly is up a remarkable 97.38% over the past year and 55.32% year-to-date. Strong technical indicators suggest continued m...

 novo-nordisk-to-restrict-initial-wegovy-sales-in-china-amid-high-demand

Novo Nordisk will limit initial sales of Wegovy in China to manage global supply and address the rising obesity rates in the wo...

 ben--jerrys-co-founders-not-worried-about-ozempics-impact-on-ice-cream-business-heres-why

Ben Cohen and Jerry Greenfield, the co-founders of Ben & Jerry's, are not worried about the impact of weight-loss drugs...

 active-fund-managers-bet-these-6-stocks-will-trade-near-all-time-highs

Active fund managers making large bets on momentum plays indicate confidence that Big Tech's rally has legs for the remaind...

 cantor-fitzgerald-reiterates-overweight-on-eli-lilly-and-co-maintains-885-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.

 novo-nordisks-older-generation-weight-loss-drug-saxenda-associated-with-decreased-bone-mass-density-study-shows

Novo Nordisk's Saxenda study published in JAMA Network Open reveals significant declines in bone density among patients, ra...

 whats-going-on-with-eli-lilly-stock-on-tuesday

Eli Lilly collaborates with Microsoft-backed OpenAI to leverage generative AI for developing novel antimicrobials targeting dru...

 cantor-fitzgerald-reiterates-overweight-on-eli-lilly-and-co-maintains-885-price-target

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.

 lilly-and-openai-collaborate-to-discover-novel-medicines-to-treat-drug-resistant-bacteria

Eli Lilly and Company (NYSE:LLY) announced a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generativ...

 truist-securities-reiterates-buy-on-eli-lilly-and-co-raises-price-target-to-1000

Truist Securities analyst Srikripa Devarakonda reiterates Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target...

 whats-going-on-with-eli-lilly-shares-monday

Eli Lilly and Co (NYSE: LLY) shares are moving higher Monday following the release of positive Phase 3 trial results for its we...

 why-resmed-shares-are-trading-lower-monday

ResMed stock is trading lower Monday after Eli Lilly and Company released data from a clinical trial in regards to the treatmen...